Pharvaris N.V.

27.52 USD
-0.26 (-0.94%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Pharvaris N.V. stock is down -5.23% since 30 days ago. The next earnings date is Apr 3, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 February’s closed higher than January. 100% of analysts rate it a buy.

About Pharvaris N.V.

Pharvaris N.V. focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE) The company was incorporated in 2015 and is based in Leiden, the Netherlands.